28.03.22
24.03.22
24.03.22
22.03.22
Copenhagen, Denmark, March 22, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces that, following the receipt of the negative Trend Vote by the Committee for Medicinal Products for Human Use (CHMP) as announced on February 23, 2022...
Read more24.02.22